CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $31,000, lower than 95% of all stocks globally
- PositionOperating margin is -2213050%, lower than 95% of its Biotechnology peers (median -34.2%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
326.40MUSDvs all stocks (USD)
Revenue (TTM)
31.00KUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-0.0620xvs all stocks
52-Week Change
40.36%vs all stocks
Market Capitalization
326.40MUSDvs all stocks (USD)
Enterprise Value
118.94MUSDvs all stocks (USD)
Forward P/E
-16.54xvs Biotechnology peers
Price to Book (MRQ)
1.18xvs Biotechnology peers
Enterprise to Revenue
3.84Kxvs Biotechnology peers
Enterprise to EBITDA
-0.6760xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-29.87%vs Biotechnology peers
Return on Equity (TTM)
-80.76%vs Biotechnology peers
Revenue (TTM)
31.00KUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0020USDUpdated Jul 19, 2026Quarterly Revenue Growth
-71.40%vs Biotechnology peers
Gross Profit (TTM)
31.00KUSDvs all stocks (USD)
EBITDA (TTM)
-176.04MUSDvs all stocks (USD)
Net Income (TTM)
-246.41MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-71.43%vs Biotechnology peers
Operating Cash Flow (TTM)
-133.80MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-77.38MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
36.00KUSDFY2025 · Dec 31, 2025Operating Income
-201.63MUSDvs all stocks (USD)
Pre-tax Income
-274.45MUSDFY2025 · Dec 31, 2025Net Income
-274.45MUSDFY2025 · Dec 31, 2025EBIT
-201.63MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-122.31MUSDFY2025 · Dec 31, 2025Research & Development
158.68MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
45.13MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.08MUSDFY2025 · Dec 31, 2025EPS (Basic)
-16.06USDFY2025 · Dec 31, 2025EPS (Diluted)
-16.06USDFY2025 · Dec 31, 2025Basic Shares Outstanding
17.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
17.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-274.45MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-164.25MUSDFY2025 · Dec 31, 2025Free Cash Flow
-164.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
61.77MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-274.45MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.54MUSDFY2025 · Dec 31, 2025Stock-based Compensation
41.83MUSDFY2025 · Dec 31, 2025Other Non-cash Items
61.91MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-2.34MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-2.74MUSDFY2025 · Dec 31, 2025Capital Expenditures
-493.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-278.90MUSDFY2025 · Dec 31, 2025Sale of Investments
374.68MUSDFY2025 · Dec 31, 2025Other Investing Activity
-41.20MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
54.10MUSDFY2025 · Dec 31, 2025Other Financing Charges
-1.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
50.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
23.33MSharesUpdated Jul 19, 2026Float Shares
9.62MSharesUpdated Jul 19, 2026Shares Short
1.22MSharesUpdated Jul 19, 2026Short Ratio
5.02daysvs all stocks
Short % of Shares Outstanding
6.17%vs all stocks
% Held by Insiders
39.52%vs all stocks
% Held by Institutions
56.83%vs all stocks
Total Cash (MRQ)
254.02MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
10.89USDUpdated Jul 19, 2026Total Debt (MRQ)
48.85MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1785xvs Biotechnology peers
Current Ratio (MRQ)
7.24xvs Biotechnology peers
Book Value per Share (MRQ)
11.73USDUpdated Jul 19, 2026Total Assets
340.05MUSDvs all stocks (USD)
Total Current Assets
260.94MUSDFY2025 · Dec 31, 2025Total Liabilities
91.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
79.11MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
42.44MUSDFY2025 · Dec 31, 2025Total Current Liabilities
49.41MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
60.18MUSDFY2025 · Dec 31, 2025Other Short-term Investments
187.04MUSDFY2025 · Dec 31, 2025Accounts Payable
2.89MUSDFY2025 · Dec 31, 2025Short-term Debt
9.07MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.54MUSDFY2025 · Dec 31, 2025Other Current Liabilities
2.56MUSDFY2025 · Dec 31, 2025Long-term Debt
41.92MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
517.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.62BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
248.20MUSDvs all stocks (USD)
52-Week Low
9.28USDUpdated Jul 19, 202652-Week High
45.00USDUpdated Jul 19, 202652-Week Change
40.36%vs all stocks
Beta
-0.0620xvs all stocks
50-Day MA
15.21USDUpdated Jul 19, 2026200-Day MA
20.85USDUpdated Jul 19, 2026Avg 10-Day Volume
182.24KSharesUpdated Jul 19, 2026Avg 30-Day Volume
230.02KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-13.62USDUpdated Jul 19, 2026Other Income / Expense
-85.90MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
High Equity Share With Elevated Lease Share of Assets
Little debt against its assets, but leases are a large share of what it holds.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Where is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -2213050%, lower than 95% of its Biotechnology peers (median -34.2%)Significant
Operating margin: -22,130.5Industry median: -0.34Industry P5: -43.55Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $31,000, lower than 95% of all stocks globallySignificant
Revenue (USD): 31,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Vanda Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Arqit Quantum Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Troops Inc.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownHigh Equity Share With Elevated Lease Share of Assets
Wave Life Sciences Ltd.
3 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedDecline With Range Expansion And DrawdownMulti-Year Debt Decrease With Cash Near Total Debt And Equity